Century Therapeutics, Inc.

# Signal Note: Casdin Capital Initiates IPSC Position Casdin's entry into Century Therapeutics suggests conviction in the company's induced pluripotent stem cell (iPSC) platform for cell therapy, particularly its lead program CNTY-101 (allogeneic CAR-T for relapsed/refractory NHL). The $1.2M position is modest in absolute terms but notable given Casdin's track record of early-stage platform bets; key catalysts include Phase 1b data readouts and potential partnership announcements over the next 12-18 months. The timing aligns with broader institutional interest in off-the-shelf cell therapies as alternatives to autologous CAR-T manufacturing constraints.